PHE855 Continues to Show High, Durable Responses in R/R Multiple Myeloma
Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.
United States Dana Farber Cancer Institute Adams Sperling Relapsed Or Refractory Multiple Myeloma Phase 1 Study Car Product
Source: targetedonc.com